Drug Patents owned by Cumberland Pharms
1. Drug name - ACETADOTE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
| US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
| US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(3 years from now) | |
| US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(8 years from now) | |
| US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(9 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 6GM/30ML (200MG/ML) | INJECTABLE;INTRAVENOUS | Prescription |
2. Drug name - CALDOLOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
| US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(7 years from now) | |
| US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) | |
| US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) | |
Drugs and Companies using IBUPROFEN ingredient
Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 400MG/4ML (100MG/ML) | SOLUTION;INTRAVENOUS | Discontinued |
| 800MG/8ML (100MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 800MG/200ML (4MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
3. Drug name - VIBATIV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6635618 | CUMBERLAND PHARMS | Glycopeptide phosphonate derivatives |
Sep, 2023
(11 months from now) | |
| US7531623 | CUMBERLAND PHARMS | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(4 years from now) | |
| CN100532392C | CUMBERLAND PHARMS | Reductive Alkylation Method |
May, 2021
(1 year, 5 months ago) | |
| CN100469788C | CUMBERLAND PHARMS | Glycopeptide Phosphonic Acid Salt Derivatives |
May, 2021
(1 year, 5 months ago) | |
| CN1432023A | CUMBERLAND PHARMS | Reductive Alkylation Process |
May, 2021
(1 year, 5 months ago) | |
| CN1437611A | CUMBERLAND PHARMS | Glycopeptide Phosphonic Acid Salt Derivatives |
May, 2021
(1 year, 5 months ago) | |
| CN1223378C | CUMBERLAND PHARMS | Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin |
May, 2021
(1 year, 5 months ago) | |
| CN1441680A | CUMBERLAND PHARMS | Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin |
May, 2021
(1 year, 5 months ago) | |
| CN1871253A | CUMBERLAND PHARMS | Hydrochloride Of Glycopeptide Phosphonate Derivatives |
Oct, 2024
(2 years from now) | |
| CN100417661C | CUMBERLAND PHARMS | Hydrochloride Of Glycopeptide Phosphonate Derivatives |
Oct, 2024
(2 years from now) | |
| IN200201986P4 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2021
(1 year, 5 months ago) | |
| IN206947B | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2021
(1 year, 5 months ago) | |
| EP1276759B1 | CUMBERLAND PHARMS | Reductive Alkylation Process On Glycopeptides |
Apr, 2021
(1 year, 5 months ago) | |
| EP1278549B1 | CUMBERLAND PHARMS | Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic |
Apr, 2021
(1 year, 5 months ago) | |
| EP1276759A2 | CUMBERLAND PHARMS | Reductive Alkylation Process On Glycopeptides |
Apr, 2021
(1 year, 5 months ago) | |
| EP1278549A2 | CUMBERLAND PHARMS | Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic |
Apr, 2021
(1 year, 5 months ago) | |
| EP1292611A2 | CUMBERLAND PHARMS | Glycopeptide Carboxy-Saccharide Derivatives |
May, 2021
(1 year, 5 months ago) | |
| EP1292611B1 | CUMBERLAND PHARMS | Glycopeptide Carboxy-Saccharide Derivatives |
May, 2021
(1 year, 5 months ago) | |
| EP1678201A2 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP1678201B1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP2495251B1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP2495251A1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP1292612B1 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2026
(3 years from now) | |
| EP1292612A2 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2026
(3 years from now) | |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
Treatment: NA
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 250MG BASE/VIAL | POWDER;INTRAVENOUS | Discontinued |
| EQ 750MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.